← Back to Search

CHAMPS for Psychosis (CHAMPS Trial)

N/A
Waitlist Available
Led By Didier Jutras-Aswad, MD, MSc
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
currently using cannabis (at least one time in the past 4 weeks);
diagnosed with any psychotic disorder, which can include schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, delusional disorder, psychotic disorder not otherwise specified, brief psychotic disorder and substance-induced psychotic disorder;
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks -2-0 (baseline), 6, 12 and 18
Awards & highlights

CHAMPS Trial Summary

This trial is testing an app called CHAMPS that gives cannabis users strategies for safer use. The goals of the study are to see if the app is acceptable to users and if it has positive impacts on their health and cannabis consumption habits.

Eligible Conditions
  • Psychosis
  • Young Adults
  • Cannabis Use

CHAMPS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have used cannabis at least once in the last 4 weeks.
Select...
You have been diagnosed with a mental disorder that can cause hallucinations or delusions, such as schizophrenia or bipolar disorder with psychotic features.
Select...
You are willing to adjust your use of cannabis.
Select...
You have been diagnosed with a mental disorder that can cause hallucinations or severe disturbances in thinking and behavior.
Select...
You have used cannabis within the past 4 weeks.
Select...
You are willing to make changes to your cannabis-related habits.

CHAMPS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks -2-0 (baseline), 6, 12 and 18
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks -2-0 (baseline), 6, 12 and 18 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Completion rates
Retention rates
Secondary outcome measures
Acceptability (CHAMPS usage data)
Efficacy (motivation to change cannabis protective behavioral strategies)
Efficacy (use of cannabis protective behavioral strategies)
+2 more
Other outcome measures
Cannabis use
Cannabis-related problems
Health service utilization
+5 more

CHAMPS Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: CHAMPS and EISExperimental Treatment1 Intervention
The Cannabis Harm-reducing App for Managing Practices Safely (CHAMPS) is a brief harm reduction e-intervention based on the principles of motivational interviewing and harm reduction approaches. This e-intervention will be completed by the participant using a smart phone. There will be a total of six individual sessions each lasting 15-20 min. There will be one booster session offered at 4 weeks post-intervention to review goal setting, evaluate motivation around changing cannabis use practices. This e-intervention will be administered adjunctively to psychosis early intervention services (EIS).
Group II: EIS aloneActive Control1 Intervention
Early intervention services (EIS) for psychosis will be offered as per standard of care at participating clinical sites. Theses services vary but typically include pharmacotherapy and individual and/or group psychotherapy. Any visits and services offered in the EIS arm will be considered 'usual care' and administered either through in-person clinic visits, phone calls, or video calls. Relevant service information will be collected for study purposes.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CHAMPS
2010
N/A
~600

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
365 Previous Clinical Trials
129,209 Total Patients Enrolled
Ministere de la Sante et des Services SociauxOTHER
17 Previous Clinical Trials
78,032 Total Patients Enrolled
Didier Jutras-Aswad, MD, MScPrincipal InvestigatorCentre hospitalier de l'Université de Montréal (CHUM)
1 Previous Clinical Trials
100 Total Patients Enrolled

Media Library

CHAMPS Clinical Trial Eligibility Overview. Trial Name: NCT04968275 — N/A
Psychosis Research Study Groups: CHAMPS and EIS, EIS alone
Psychosis Clinical Trial 2023: CHAMPS Highlights & Side Effects. Trial Name: NCT04968275 — N/A
CHAMPS 2023 Treatment Timeline for Medical Study. Trial Name: NCT04968275 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many facilities are managing this clinical trial?

"For this trial, 5 sites are accepting participants: Clinic Notre-Dame des Victoires - Centre de Recherche CERVO in Québec; Nova Scotia Early Psychosis Program in Halifax; Clinique JAP at the Centre hospitalier de l'Université de Montréal and 2 other medical centres."

Answered by AI

Does this research project remain open to new participants?

"According to clinicaltrials.gov, this medical study is not actively enrolling patients at the moment; it was first posted on August 23rd 2021 and last updated September 13th 2021. However, there are 554 other trials that currently require participants for their research."

Answered by AI

Is the cutoff age for inclusion in this experiment restricted to those below 45 years?

"As detailed in the eligibility requirements, this medical trial is limited to individuals between 18 and 35 years of age. For patients outside of this range, there are 130 research studies dedicated to those below 18 years old and 308 for participants over 65."

Answered by AI

What is the objective of this investigation?

"The primary metric of success for this 12-week trial is participant retention. Secondary objectives revolve around efficacy and satisfaction, as measured by changes in the Readiness-to-Change Questionnaire modified for cannabis use, the Short Form Protective Behavioral Strategies-Marijuana questionnaire., and a Client Satisfaction Questionnaire respectively."

Answered by AI

What criteria must potential participants fulfill to be considered for this clinical trial?

"This experiment is aiming to recruit 100 young adults with ages ranging from 18-35. To be eligible, participants must ensure that: they are available for the full duration of the study and able to follow through on its procedures; not have used cannabis in the past 4 weeks; open to making changes related to their cannabis consumption; free of any psychiatric disorder such as schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features or others specified under substance-induced psychosis."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What site did they apply to?
Clinique JAP, Centre hospitalier de l'Université de Montréal, 1051, rue Sanguinet
What portion of applicants met pre-screening criteria?
Met criteria
~28 spots leftby Mar 2025